Evidence map›Paper›PMID 40785550›Full record

ReviewAllergy2025

IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets.

Louisa Tedesco, Syed B Ali, Baran Erman, Safa Baris, Harshita Pant, Pravin Hissaria, Yelda Bilginer, Damon J Tumes, Gökhan Cildir

Abstract readReview
In one paragraph

Review in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Louisa TedescoCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.ORCID https://orcid.org/0009-0000-8828-3217
Syed B AliDepartment of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia.ORCID https://orcid.org/0000-0002-4103-6953
Baran ErmanCan Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-9398-8465
Safa BarisFaculty of Medicine, Division of Pediatric Allergy and Immunology, Marmara University, Istanbul, Türkiye.ORCID https://orcid.org/0000-0002-4730-9422
Harshita PantDiscipline of Medicine, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Pravin HissariaAdelaide Medical School, University of Adelaide, Adelaide, Australia; Division of Human Immunology, SA Pathology, Adelaide, Australia; Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.
Yelda BilginerDepartment of Pediatric Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Damon J TumesCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
Gökhan CildirCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.ORCID https://orcid.org/0000-0001-7457-9164

Funding

National Health and Medical Research Council (NHMRC) 2027602
6 · The paper itself

Abstract

IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half-molecules (one heavy chain and one light chain) and its generally non-inflammatory nature, distinguish it from other IgG subclasses. Its role in immune dysregulation is further underscored by a distinct disease entity called IgG4-related disease (IgG4-RD), a systemic fibroinflammatory disorder characterised by IgG4

Indexed as

Genetic VariationImmunoglobulin GImmunoglobulin G4-Related DiseaseAnimalsBiomarkersGenetic Predisposition to DiseaseHumansMolecular Targeted TherapyBiomarkersImmunoglobulin GfibrosisIgG4IgG4‐related diseaseimmune dysregulationinebilizumab

Identifiers

PMID40785550
PMCPMC12486373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.